FrancophonIA/ELRC3.0 huggingface dataset:
English: • Fits, shaking, or difficulty speaking or slurred speech, loss of consciousness or decreased level of consciousness, confusion and disorientation, loss of balance or coordination.
Croatian: • napadaje, drhtanje ili poteškoće pri govoru ili nerazgovijetan govor, gubitak svijesti ili smanjena razina svijesti, smetenost i dezorijentacija, gubitak ravnoteže ili koordinacije
English: Most patients recovered from neurologic adverse reactions, with the exception of 4 patients who had ongoing neurologic adverse reactions at the time of death; the deaths were due to other causes.
Croatian: Većina se bolesnika oporavila od neuroloških nuspojava, osim 4 bolesnika u kojih su neurološke nuspojave bile prisutne u vrijeme smrti; njihova smrt bila je posljedica drugih uzroka.
English: Age (range: 23 to 76 years) and sex had no significant impact on AUC and Cmax of YESCARTA.
Croatian: Dob (u rasponu od 23 do 76 godina) i spol nisu imali značajan utjecaj na vrijednosti AUC i Cmax lijeka YESCARTA.
English: YESCARTA should only be given if the results show you are not pregnant.
Croatian: Lijek YESCARTA smije se dati samo ako nalaz pokaže da niste trudni.
English: Serious adverse reactions occurred in 56% of patients.
Croatian: Ozbiljne nuspojave pojavile su se u 56% bolesnika.
English: • Place the infusion bag inside a second sterile bag or per local guidelines.
Croatian: • Vrećicu infuzije stavite u drugu sterilnu vrećicu ili prema nacionalnim smjernicama.
English: - If YESCARTA infusion is delayed for more than 2 weeks after you have received preparatory chemotherapy you may have to receive more preparative chemotherapy.
Croatian: Ako je infuzija lijeka YESCARTA odgođena za više od 2 tjedna nakon što ste primili pripremnu kemoterapiju, možda ćete morati primiti dodatnu pripremnu kemoterapiju.
English: Pregnant women should be advised on the potential risks to the foetus.
Croatian: Trudnice treba upozoriti na moguće rizike za fetus.
English: Nearly all patients experienced some degree of CRS.
Croatian: U gotovo svih bolesnika razvio se neki stupanj CRS-a.
English: YESCARTA is a type of medicine called a “genetically modified cell therapy”.
Croatian: YESCARTA je vrsta lijeka koja se naziva „terapija genetički modificiranim stanicama“.
English: YESCARTA should not be used in children and adolescents below 18 years of age.
Croatian: Lijek YESCARTA ne smije se primjenjivati u djece i adolescenata mlađih od 18 godina.
English: Annual safety reports and 5-yearly interim reports
Croatian: • Ažurirati izvješća: godišnja izvješća o sigurnosti primjene lijeka i petogodišnja privremena izvješća
English: Other medicines and YESCARTA
Croatian: Drugi lijekovi i YESCARTA
English: • Your doctor or nurse will give you a single infusion of YESCARTA into your vein for approximately 30 minutes.
Croatian: • Liječnik ili medicinska sestra dat će Vam jednu infuziju lijeka YESCARTA u venu, što će trajati približno 30 minuta.
English: However, YESCARTA infusion should begin within 30 minutes of thaw completion and the total YESCARTA infusion time should not exceed 30 minutes.
Croatian: Međutim, infuziju lijeka YESCARTA treba započeti u roku od 30 minuta od završenog odmrzavanja, a ukupno vrijeme infuzije lijeka YESCARTA ne smije premašiti 30 minuta.
English: Talk to your doctor if you need to have any vaccinations.
Croatian: Obratite se liječniku ako trebate primiti bilo koje cjepivo.
English: Do not donate blood, organs, tissues or cells for transplants.
Croatian: Nemojte darivati krv, organe, tkiva ili stanice za transplantaciju.
English: Before you are given YESCARTA tell your doctor or nurse if you are taking any medicines that weaken your immune system such as corticosteroids, since these medicines may interfere with the effect of YESCARTA.
Croatian: Prije nego što primite lijek YESCARTA obavijestite svog liječnika ili medicinsku sestru ako uzimate bilo kakve lijekove koji slabe imunosni sustav kao što su kortikosteroidi, budući da ti lijekovi mogu utjecati na učinak lijeka YESCARTA.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this medicine.
Croatian: Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego primite ovaj lijek.
English: Patient Educational program
Croatian: Edukacijski program za bolesnike
English: Kite Patient ID:
Croatian: Kite ID bolesnika:
English: Sodium chloride Human albumin
Croatian: natrijev klorid ljudski albumin
English: Dysphagia is a recognised symptom of encephalopathy which is currently listed in the product information; however, dysphagia can lead to serious complications and may require specific clinical measures.
Croatian: Disfagija je prepoznati simptom encefalopatije koji je trenutno naveden u informacijama o lijeku, međutim, disfagija može dovesti do ozbiljnih komplikacija i može zahtijevati posebne kliničke mjere.
English: CR rates were 75% and 56%, respectively.
Croatian: Stope CR-a bile su 75% odnosno 56%.
English: This is because the effects of YESCARTA in pregnant or breast-feeding women are not known, and it may harm your unborn baby or your breast-fed child.
Croatian: To je zbog toga što učinci lijeka YESCARTA u trudnica ili dojilja nisu poznati i mogu naštetiti vašem nerođenom djetetu ili dojenčetu.
English: A summary of the patient demographics is provided in Table 4.
Croatian: Sažetak demografskih podataka bolesnika naveden je u tablici 4.
English: Nine patients were not treated, primarily due to progressive disease or serious adverse events after enrolment and prior to cell delivery.
Croatian: Devet bolesnika nije liječeno prvenstveno zbog progresivne bolesti ili ozbiljnih štetnih događaja nakon uključivanja i prije primanja stanica.
English: Hence, traditional toxicology studies used for drug development were not performed.
Croatian: Stoga nisu provedena tradicionalna toksikološka ispitivanja za razvoj lijeka.
English: Infections occurred in 39% of patients in ZUMA-1.
Croatian: Infekcije su se pojavile u 39% bolesnika u ispitivanju ZUMA-1.
English: Your doctor will take some of your blood using a catheter placed in your vein (a procedure call leukapheresis).
Croatian: Liječnik će Vam izvaditi malo krvi pomoću katetera umetnutog u venu (taj se postupak naziva leukaferezom).
English: See section 2 “YESCARTA contains sodium”.
Croatian: Pogledajte u dijelu 2. „Lijek YESCARTA sadrži natrij.“
English: No studies have been conducted to evaluate the effects of YESCARTA on fertility, reproduction, and development.
Croatian: Nisu provedena ispitivanja za procjenu učinaka lijeka YESCARTA na plodnost, reprodukciju i razvoj.
English: Peak elevation was observed within the first 14 days after infusion, and levels generally returned to baseline within 28 days.
Croatian: Najveće povećanje opaženo je u prvih 14 dana nakon infuzije, a razine su se uglavnom vratile na početne vrijednosti u roku od 28 dana.
English: YESCARTA has major influence on the ability to drive and use machines.
Croatian: YESCARTA značajno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Signs and symptoms of TLS should be monitored and events managed according to standard guidelines.
Croatian: Znakove i simptome STL-a treba pratiti i događaje zbrinjavati prema standardnim smjernicama.
English: Availability of tocilizumab and site qualification
Croatian: Dostupnost tocilizumaba i kvalificirana bolnička ustanova
English: Symptoms require and respond to moderate intervention.
Croatian: Simptomi zahtijevaju i odgovaraju na umjerenu intervenciju.
English: To minimise the risks associated with the treatment of YESCARTA, the MAH must ensure that hospitals and their associated centres that dispense YESCARTA are specially qualified in accordance with the agreed control distribution program.
Croatian: Radi minimizacije rizika povezanih s liječenjem lijekom YESCARTA, nositelj odobrenja mora osigurati da su bolnice i njihovi povezani centri koji primjenjuju lijek YESCARTA posebno kvalificirani u skladu s dogovorenim programom kontrolirane distribucije.
English: Manage per Grade 3 if no improvement within 24 hours after starting tocilizumab.
Croatian: Liječiti kao 3. stupanj ako nema poboljšanja u roku od 24 sata od početka primjene tocilizumaba.
English: This medicine contains 300 mg sodium (main component of cooking/table salt) in each infusion.
Croatian: Ovaj lijek sadrži 300 mg natrija (glavni sastojak kuhinjske soli) u jednoj infuziji.
English: The median duration of follow up was 27.1 months (still ongoing).
Croatian: Medijan trajanja praćenja bio je 27,1 mjesec (još uvijek u tijeku).
English: Overall Survival, median (months) [95% CI]
Croatian: Ukupno preživljenje, medijan (mjeseci) [95% CI]
English: Do not refreeze.
Croatian: Nemojte ponovno zamrzavati.
English: Your doctor may need to take special care of you during your treatment with YESCARTA.
Croatian: Možda će Vas liječnik morati posebno nadzirati tijekom liječenja lijekom YESCARTA.
English: YESCARTA is intended solely for autologous use and must not be administered to other patients.
Croatian: Lijek YESCARTA namijenjen je isključivo za autolognu primjenu i ne smije se primjenjivati u drugih bolesnika.
English: No reproductive and developmental toxicity animal studies have been conducted with YESCARTA to assess whether it can cause foetal harm when administered to a pregnant woman (see section 5.3).
Croatian: Nisu provedena ispitivanja reproduktivne i razvojne toksičnosti u životinja koja bi procijenila može li lijek YESCARTA uzrokovati oštećenje fetusa kada se primjenjuje u trudnica (vidjeti dio 5.3).
English: 1098 XH Amsterdam The Netherlands
Croatian: 1098 XH Amsterdam Nizozemska
English: Each bag of YESCARTA contains 300 mg sodium.
Croatian: Jedna vrećica lijeka YESCARTA sadrži 300 mg natrija.
English: These events were considered as syndromes of neurologic toxicity, an important identified risk of axicabtagene ciloleucel use.
Croatian: Ovi su se događaji smatrali sindromima neurološke toksičnosti, važnim identificiranim rizikom primjene aksikaptagen ciloleucela.
English: Due to the potential for neurologic events, including altered mental status or seizures, patients should refrain from driving or operating heavy or potentially dangerous machines until at least 8 weeks after infusion or until resolution of neurologic adverse reactions.
Croatian: Zbog moguće pojave neuroloških događaja, uključujući izmijenjeno mentalno stanje ili napadaje, bolesnici ne smiju upravljati vozilima ili rukovati teškim ili potencijalno opasnim strojevima do najmanje 8 tjedana nakon infuzije ili do povlačenja neuroloških nuspojava.
English: Kite Pharma, Inc. 2355 Utah Avenue El Segundo California CA 90245
Croatian: Kite Pharma, Inc. 2355 Utah Avenue El Segundo
English: Levels of cytokines and chemokines such as IL-6, IL-8, IL-10, IL-15, TNF-α, IFN-γ, and IL2Rα were analyzed.
Croatian: Analizirane su razine citokina i kemokina kao što su IL-6, IL-8, IL-10, IL-15, TNF-α, IFN-γ i IL2Rα.
English: Take your temperature twice a day for 3-4 weeks after treatment with YESCARTA.
Croatian: Temperaturu trebate mjeriti dvaput dnevno još 3 do 4 tjedna nakon liječenja lijekom YESCARTA.
English: The ORR was prespecified to be tested in the first 92 treated patients and was significantly higher than the prespecified rate of 20% (P < 0.0001).
Croatian: Stopa objektivnog odgovora bila je unaprijed određena za testiranje prva 92 liječena bolesnika, i bila je značajno viša od unaprijed određene stope od 20% (P < 0,0001).
English: In some cases, it might not be possible to go ahead with the planned treatment with YESCARTA.
Croatian: U nekim slučajevima možda neće biti moguće nastaviti liječenje lijekom YESCARTA kako je planirano.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CONTAINER (CASSETTE)
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKI SPREMNIK (KAZETA)
English: Alanine aminotransferase increased Aspartate aminotransferase increased
Croatian: Pretrage vrlo često povišena alanin aminotransferaza povišena aspartat aminotransferaza često povišen bilirubin
English: Administer tocilizumab (c) 8 mg/kg intravenously over 1 hour (not to exceed 800 mg).
Croatian: Intravenski primijeniti 8 mg/kg tocilizumaba (c) tijekom 1 sata (ne premašiti 800 mg).
English: Taking into account the PRAC Assessment Report on the PSUR(s) for axicabtagene ciloleucel, the scientific conclusions of CHMP are as follows:
Croatian: Uzimajući u obzir PRAC-ovo izvješće o ocjeni periodičkog(ih) izvješća o neškodljivosti lijeka (PSUR) za aksikaptagen ciloleucel, znanstveni zaključci CHMP-a su sljedeći:
English: Educational program - Prior to the launch of YESCARTA in each Member State the MAH must agree the content and format of the educational materials with the National Competent Authority.
Croatian: Edukacijski program - Prije puštanja lijeka YESCARTA u promet, nositelj odobrenja mora u svakoj državi članici dogovoriti sadržaj i oblik edukacijskih materijala s nacionalnim nadležnim tijelom.
English: Three patients tested positive for anti-FMC63 prior to being treated with YESCARTA.
Croatian: Tri bolesnika bila su pozitivna na anti-FMC63 prije liječenja lijekom YESCARTA.
English: Some of your white blood cells are separated from your blood and the rest of your blood is returned to your vein.
Croatian: Iz krvi će Vam izdvojiti nešto leukocita, a ostatak krvi vraća se u venu.
English: • Infuse the entire content of the YESCARTA bag within 30 minutes by either gravity or a peristaltic pump.
Croatian: • Cjelokupni sadržaj vrećice lijeka YESCARTA infuzijski primijenite u roku od 30 minuta pomoću gravitacije ili peristaltičke pumpe.
English: You may be given medicines to help prevent the condition.
Croatian: Možda ćete dobiti lijekove koji sprječavaju pojavu tog stanja.
English: • A leukodepleting filter must not be used.
Croatian: • Ne smije se upotrebljavati leukodeplecijski filtar.
English: Patients were not required to be followed after they progressed; thus, the majority of patients with evaluable samples were responders.
Croatian: Bolesnike nije bilo potrebno pratiti nakon progresije, tako da su većinu bolesnika s procjenjivim uzorcima činili oni s terapijskim odgovorom.
English: All leukapheresed (ITT) Cohort 1 + 2 (N = 111)
Croatian: Sve leukafereze (ITT) Kohorta 1 + 2 (N = 111)
English: STOP confirm patient ID prior to infusion.
Croatian: STANITE i potvrdite identitet bolesnika prije infuzije.
English: YESCARTA will only be supplied to hospitals and associated centres that are qualified and only if the healthcare professionals involved in the treatment of a patient have completed the educational program.
Croatian: Lijek YESCARTA smije se isporučiti samo kvalificiranim bolnicama i povezanim centrima te samo ako su zdravstveni radnici uključeni u liječenje bolesnika završili edukacijski program.
English: • You will be given a pregnancy test before treatment starts.
Croatian: • Prije početka liječenja obavit će Vam se test na trudnoću.
English: * Dysphagia has been reported in the setting of neurologic toxicity and encephalopathy
Croatian: * Disfagija je zabilježena kod neurološke toksičnosti i encefalopatije
English: YESCARTA should not be washed, spun down, and/or re-suspended in new media prior to infusion.
Croatian: Lijek YESCARTA ne smije se ispirati, centrifugirati i/ili ponovno suspendirati u novom mediju prije infuzije.
English: In the phase 1 part of ZUMA-1, 7 patients were treated.
Croatian: U fazi 1 ispitivanja ZUMA-1 liječeno je 7 bolesnika.
English: Patients with human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
Croatian: Bolesnici zaraženi virusom humane imunodeficijencije (HIV), virusom hepatitisa B (HBV) i virusom hepatitisa C (HCV)
English: YESCARTA comprises engineered human T cells, therefore there are no representative in vitro assays, ex vivo models, or in vivo models that can accurately address the toxicological characteristics of the human product.
Croatian: YESCARTA se sastoji od genetički modificiranih ljudskih T-stanica, tako da ne postoje reprezentativni in vitro testovi, ex vivo modeli niti in vivo modeli koji mogu dati precizan odgovor u vezi toksikoloških značajki ljudskog proizvoda.
English: • If you are pregnant or think you may be pregnant after treatment with YESCARTA, talk to your doctor immediately.
Croatian: • Ako ste trudni ili mislite da biste mogli biti trudni nakon liječenja lijekom YESCARTA, odmah se obratite svom liječniku.
English: If no improvement within 24 hours after starting tocilizumab, administer dexamethasone 10 mg intravenously every 6 hours if not already taking other corticosteroids.
Croatian: Ako ne dođe do poboljšanja u roku od 24 sata od početka primjene tocilizumaba, intravenski primijeniti 10 mg deksametazona svakih 6 sati ako bolesnik već ne uzima druge kortikosteroide.
English: A retrospective, patient-level, pooled analysis of outcomes in refractory aggressive NHL (N = 636) was conducted (Crump et al., 2017) to provide confirmation of the prespecified control response rate of 20% and historical context for interpreting the ZUMA-1 results.
Croatian: Provedena je retrospektivna, objedinjena analiza ishoda na razini bolesnika s refraktornim agresivnim NHL-om (N = 636) (Crump et al., 2017.) kako bi se dobila potvrda za unaprijed određenu kontrolnu stopu odgovora od 20% i povijesni kontekst za tumačenje rezultata ispitivanja ZUMA-1.
English: • Plan to stay within proximity from the hospital where you were treated for at least 4 weeks after you have been given YESCARTA.
Croatian: • Planirajte ostati u blizini bolnice u kojoj ste liječeni najmanje 4 tjedna nakon primanja lijeka YESCARTA.
English: The ORR was 26% [95% CI (21, 31)] and the CR rate was 7% [95% CI (3, 15)], with a median OS of 6.3 months.
Croatian: ORR je bio 26% [95% CI (21; 31)] dok je stopa CR-a bila 7% [95% CI (3; 15)], s medijanom OS-a od 6,3 mjeseca.
English: Non-interventional post-authorisation safety study (PASS): In order to assess the safety profile including long term safety in patients with B-lymphocyte malignancies treated with axicabtagene ciloleucel in the post marketing setting, the applicant should conduct and submit a study based on a registry.
Croatian: Neintervencijsko ispitivanje sigurnosti primjene lijeka nakon davanja odobrenja za stavljanje lijeka u promet (PASS): Kako bi se procijenio sigurnosni profil, uključujući dugoročnu sigurnost u bolesnika s B-limfocitnim malignitetima liječenih aksikaptagen ciloleucelom nakon stavljanja lijeka u promet, podnositelj zahtjeva treba provesti i dostaviti ispitivanje na osnovi registra.
English: Patients treated with YESCARTA may develop secondary malignancies.
Croatian: U bolesnika liječenih lijekom YESCARTA mogu se razviti sekundarni maligniteti.
English: Eligible patients were ≥ 18 years of age with refractory disease defined as progressive disease (PD) or stable disease (SD) as best response to last line of therapy, or disease progression within 12 months after autologous stem cell transplant (ASCT).
Croatian: ≥ 18 godina s refraktornom bolesti definiranom kao progresivna bolest (engl. progressive disease, PD) ili stabilna bolest (engl. stable disease, SD) kao najbolji odgovor na zadnju liniju terapije ili kao progresija bolesti u 12 mjeseci nakon autologne transplantacije matičnih stanica (engl. autologous stem cell transplant, ASCT).
English: Therefore, YESCARTA is not recommended for women who are pregnant, or for women of childbearing potential not using contraception.
Croatian: Stoga se lijek YESCARTA ne preporučuje trudnicama niti ženama reproduktivne dobi koje ne upotrebljavaju kontracepciju.
English: Small clumps of cellular material should disperse with gentle manual mixing.
Croatian: Male nakupine staničnog materijala trebale bi se raspršiti nakon pažljivog ručnog miješanja.
English: YESCARTA is intended for autologous use only (see section 4.4).
Croatian: YESCARTA je lijek namijenjen samo za autolognu primjenu (vidjeti dio 4.4).
English: In phase 2 of ZUMA-1, after YESCARTA infusion, pharmacodynamic responses were evaluated over a 4-week interval by measuring transient elevation of cytokines, chemokines, and other molecules in blood.
Croatian: U fazi 2 ispitivanja ZUMA-1, nakon infuzije lijeka YESCARTA, procijenjeni su farmakodinamički odgovori tijekom četverotjednog intervala mjerenjem prolaznih povećanja vrijednosti citokina, kemokina i drugih molekula u krvi.
English: All treated (mITT) Cohort 1 + 2 (N = 101)
Croatian: Svi liječeni (mITT) Kohorta 1 + 2 (N = 101)
English: • Prophylactic use of systemic corticosteroids is not recommended as it may interfere with the activity of YESCARTA.
Croatian: • Ne preporučuje se profilaktička upotreba sistemskih kortikosteroida jer mogu utjecati na djelovanje lijeka YESCARTA.
English: One cryostorage bag is individually packed in a shipping cassette.
Croatian: Jedna vrećica za kriopohranu zasebno je pakirana u kazetu za isporuku.
English: Patients should be monitored for signs and symptoms of neurologic adverse reactions (Table 2).
Croatian: Bolesnike je potrebno pratiti zbog znakova i simptoma neuroloških nuspojava (tablica 2).
English: In ZUMA-1, hypogammaglobulinaemia occurred in 16% of patients.
Croatian: U ispitivanju ZUMA-1 hipogamaglobulinemija se pojavila u 16% bolesnika.
English: • An antihistamine such as diphenhydramine.
Croatian: • antihistaminik kao što je difenhidramin.
English: You must receive YESCARTA infusion in a qualified clinical facility and be discharged only when your doctor thinks it is safe for you to go home.
Croatian: Lijek YESCARTA morate primiti u specijaliziranoj bolničkoj ustanovi te će Vas otpustiti tek nakon što Vaš liječnik bude smatrao da je sigurno da idete kući.
English: • Your white blood cells are frozen and sent away to make YESCARTA.
Croatian: • Vaši će leukociti biti zamrznuti i poslani za proizvodnju lijeka YESCARTA.
English: There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with YESCARTA.
Croatian: Nema dovoljno podataka o izloženosti lijeku za davanje preporuke o trajanju kontracepcije nakon liječenja lijekom YESCARTA.
English: YESCARTA therapy should be initiated under the direction of and supervised by a healthcare professional experienced in the treatment of haematological malignancies and trained for administration and management of patients treated with YESCARTA.
Croatian: Terapiju lijekom YESCARTA treba započeti prema uputama i pod nadzorom zdravstvenog radnika iskusnog u liječenju hematoloških maligniteta i osposobljenog za primjenu i upravljanje terapijom u bolesnika liječenih lijekom YESCARTA.
English: Neurologic adverse reactions occurred in 67% of patients.
Croatian: Neurološke nuspojave pojavile su se u 67% bolesnika.
English: Febrile neutropenia was observed in 36% of patients after YESCARTA infusion.
Croatian: Febrilna neutropenija zabilježena je u 36% bolesnika nakon infuzije lijeka YESCARTA.
English: Secondary endpoints included duration of response (DOR), overall survival (OS), and severity of adverse events.
Croatian: Sekundarne mjere ishoda uključivale su trajanje odgovora (engl. duration of response, DOR), ukupno preživljenje (engl. overall survival, OS) i težinu štetnih događaja.
English: Patients with medically significant cardiac dysfunction should be managed by standards of critical care and measures such as echocardiography should be considered.
Croatian: Bolesnike s medicinski značajnom srčanom disfunkcijom treba liječiti prema standardima skrbi za kritična stanja i treba razmotriti provedbu postupaka kao što je ehokardiografija.
English: Prior treatment with anti-CD19 therapy
Croatian: Prethodno liječenje terapijom protiv CD19
English: Summary of demographics for ZUMA-1 phase 2 (12 month analysis)
Croatian: Tablica 4: Sažetak demografskih podataka u fazi 2 ispitivanja ZUMA-1 (analiza 12 mjeseci) Kategorija
English: Therefore, the risk/benefit of YESCARTA has not been established in this population.
Croatian: Stoga omjer rizika i koristi lijeka YESCARTA nije utvrđen u ovoj populaciji.